The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA is tentatively scheduled to review Vivus' obesity drug Qnexa July 15, 2010. The target date for the FDA to complete its review of the NDA is Oct. 28, 2010. Vivus release
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments